Published in Arch Gen Psychiatry on April 01, 1991
Neuropsychiatric adverse effects of interferon-alpha: recognition and management. CNS Drugs (2005) 1.93
The Roles of Maternal Depression, Serotonin Reuptake Inhibitor Treatment, and Concomitant Benzodiazepine Use on Infant Neurobehavioral Functioning Over the First Postnatal Month. Am J Psychiatry (2015) 1.45
Treatment-resistant depression: therapeutic trends, challenges, and future directions. Patient Prefer Adherence (2012) 1.01
Metabolism and pharmacokinetics of selective serotonin reuptake inhibitors. Cell Mol Neurobiol (1999) 0.96
Single-action versus dual-action antidepressants. Prim Care Companion J Clin Psychiatry (2004) 0.91
Duloxetine in the treatment of major depressive disorder. Neuropsychiatr Dis Treat (2007) 0.89
Duloxetine: A New Treatment for the Emotional and Physical Symptoms of Depression. Prim Care Companion J Clin Psychiatry (2003) 0.85
Co-prescribing of SSRIs and TCAs in Australia: how often does it occur and who is doing it? Br J Clin Pharmacol (2001) 0.84
Is increased antidepressant exposure a contributory factor to the obesity pandemic? Transl Psychiatry (2016) 0.82
Comparative effects of duloxetine and desipramine on sleep EEG in healthy subjects. Psychopharmacology (Berl) (2004) 0.81
Translating evidence on depression and physical symptoms into effective clinical practice. Prim Care Companion J Clin Psychiatry (2007) 0.78
An Evidence-Based Approach to Augmentation and Combination Strategies for: Treatment-Resistant Depression. Psychiatry (Edgmont) (2006) 0.78
The strategy of combining antidepressants in the treatment of major depression: clinical experience in spanish outpatients. Depress Res Treat (2011) 0.77
Polymorphism in the metabolism of drugs, including antidepressant drugs: comments on phenotyping. J Psychiatry Neurosci (1994) 0.77
Managing resistant depression. When patients do not respond to therapy. Can Fam Physician (1993) 0.76
Preclinical pharmacology of F-98214-TA, a novel potent serotonin and norepinephrine uptake inhibitor with antidepressant and anxiolytic properties. Psychopharmacology (Berl) (2005) 0.76
Use of treatment algorithms for depression. Prim Care Companion J Clin Psychiatry (2006) 0.76
Fluoxetine inhibits desipramine metabolism. Arch Gen Psychiatry (1992) 0.75
Managing selective serotonin reuptake inhibitor-drug interactions in clinical practice. Clin Pharmacokinet (1995) 0.75
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry (1994) 8.88
Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS). J Trauma Stress (1998) 3.07
Development and preliminary psychometric properties of an instrument for the measurement of childhood trauma: the Early Trauma Inventory. Depress Anxiety (2000) 2.30
Rab27a enables myosin Va-dependent melanosome capture by recruiting the myosin to the organelle. J Cell Sci (2001) 2.09
Childhood sexual abuse as a risk factor for depression in women: psychosocial and neurobiological correlates. Am J Psychiatry (1999) 1.87
Management of the adverse effects of clozapine. Schizophr Bull (1998) 1.83
Sex differences in event-related risk for major depression. Psychol Med (2001) 1.75
Selective speech perception alterations in schizophrenic patients reporting hallucinated "voices". Am J Psychiatry (1999) 1.59
Family accommodation of obsessive-compulsive symptoms: instrument development and assessment of family behavior. J Nerv Ment Dis (1999) 1.52
Imaging D2 receptor occupancy by endogenous dopamine in humans. Neuropsychopharmacology (1997) 1.50
ECT for lorazepam-refractory catatonia. Convuls Ther (1996) 1.48
Atomic absorption determination of lead in blood and urine in the presence of EDTA. J Lab Clin Med (1971) 1.42
Gender differences in the effects of bereavement-related psychological distress in health outcomes. Psychol Med (1999) 1.29
L-dopa in senile dementia. Lancet (1970) 1.29
Acquisition and maintenance of intravenous cocaine self-administration in Lewis and Fischer inbred rat strains. Brain Res (1997) 1.26
Self-efficacy as a mediator between stressful life events and depressive symptoms. Differences based on history of prior depression. Br J Psychiatry (2000) 1.20
Desipramine facilitation of initial cocaine abstinence. Arch Gen Psychiatry (1989) 1.19
Interactive effects of subanesthetic ketamine and haloperidol in healthy humans. Psychopharmacology (Berl) (1999) 1.17
Concurrent cocaine-ethanol ingestion in humans: pharmacology, physiology, behavior, and the role of cocaethylene. Psychopharmacology (Berl) (1993) 1.15
Behavioral, physiological, and pharmacological interaction of cocaine and disulfiram in humans. Biol Psychiatry (1995) 1.13
Cocaethylene: pharmacology, physiology and behavioral effects in humans. J Pharmacol Exp Ther (1995) 1.12
Trends in prescribing psychotropic medications. JAMA (1998) 1.09
Interactive effects of subanesthetic ketamine and subhypnotic lorazepam in humans. Psychopharmacology (Berl) (1998) 1.09
Increased anxiogenic effects of caffeine in panic disorders. Arch Gen Psychiatry (1985) 1.07
Gender differences in referral to cardiac rehabilitation programs after revascularization. J Cardiopulm Rehabil (2001) 1.07
"Psychedelic" experiences in acute psychoses. Arch Gen Psychiatry (1966) 1.03
GABA levels in CSF of patients with psychiatric disorders. Am J Psychiatry (1980) 1.02
Tricyclic antidepressants: plasma levels and clinical findings in overdose. Am J Psychiatry (1978) 0.98
Clinical measurements of central dopamine and 5-hydroxytryptamine metabolism: reliability and interpretation of cerebrospinal fluid acid monoamine metabolite measures. Neuropharmacology (1972) 0.98
Platelet alpha-granule release in cocaine users. Circulation (1994) 0.98
Central dopamine turnover in schizophrenic syndromes. Arch Gen Psychiatry (1974) 0.98
Delta 9-tetrahydrocannabinol increases prefrontal cortical catecholaminergic utilization and impairs spatial working memory in the rat: blockade of dopaminergic effects with HA966. Neuropsychopharmacology (1997) 0.97
Relationship of monoamine metabolites in human cerebrospinal fluid to age. Nature (1968) 0.95
CSF monoamine metabolites in children with minimal brain dysfunction: evidence for alteration of brain dopamine. A preliminary report. J Pediatr (1977) 0.93
Psychotogenic drug use and neuroleptic response. Schizophr Bull (1990) 0.92
Central biogenic amine metabolism in children with the syndrome of chronic multiple tics of Gilles de la Tourette: norepinephrine, serotonin, and dopamine. J Am Acad Child Psychiatry (1979) 0.92
An improved Delves cup atomic absorption procedure for determination of lead in blood and urine. Clin Chem (1972) 0.92
Chronic substance-induced psychotic disorders: state of the literature. J Neuropsychiatry Clin Neurosci (1996) 0.92
Chronic, multiple tics of Gilles de la Tourette's disease. CSF acid monoamine metabolites after probenecid administration. Arch Gen Psychiatry (1978) 0.91
Gilles de la Tourette's syndrome: biochemical approaches. Res Publ Assoc Res Nerv Ment Dis (1976) 0.91
Stress-induced activation of prefrontal cortex dopamine turnover: blockade by lesions of the amygdala. Brain Res (1994) 0.89
Desipramine plasma concentration and antidepressant response. Arch Gen Psychiatry (1982) 0.88
Insight and interpretation of illness in recovery from psychosis. Schizophr Bull (1989) 0.87
Delusional unipolar depression: description and drug response. Arch Gen Psychiatry (1978) 0.87
Long-term therapy of myoclonus and other neurologic disorders with L-5-hydroxytryptophan and carbidopa. N Engl J Med (1977) 0.86
Measurement of acid monoamine metabolites in human and animal cerebrospinal fluid. J Neurochem (1968) 0.86
Gas-chromatographic analysis for cocaine in human plasma, with use of a nitrogen detector. Clin Chem (1975) 0.86
Antidepressant-associated mania and psychosis resulting in psychiatric admissions. J Clin Psychiatry (2001) 0.86
Similarities and differences between anonymous and directed candidates for oocyte donation. J Assist Reprod Genet (1995) 0.85
Dopamine and serotonin metabolism in neuropsychiatrically disturbed children. CSF homovanillic acid and 5-hydroxyindoleacetic acid. Arch Gen Psychiatry (1977) 0.85
Cocaine and cocaethylene: effects on extracellular dopamine in the primate. Psychopharmacology (Berl) (1995) 0.85
The effect of L-dopa on monoamine metabolites in Parkinson's disease. Experientia (1970) 0.85
Biochemical processes in schizophrenia: an update. Schizophr Bull (1980) 0.85
Clozapine in the treatment of aggression in an adolescent with autistic disorder. J Clin Psychiatry (2001) 0.84
Does melancholia predict response in major depression? J Affect Disord (1990) 0.84
Subjective complaints during desipramine treatment. Relative importance of plasma drug concentrations and the severity of depression. Arch Gen Psychiatry (1984) 0.84
Effect of alpha-methyl-para-tyrosine on response to cocaine challenge. Biol Psychiatry (1997) 0.84
Pretreatment plasma HVA predicts neuroleptic response in manic psychosis. J Affect Disord (1998) 0.84
Physical and sexual abuse during childhood and development of psychiatric illnesses during adulthood. J Nerv Ment Dis (1997) 0.84
The schizophrenic experience. A follow-up study of attitude and posthospital adjustment. J Nerv Ment Dis (1969) 0.83
Deficient transport mechanism for the removal of acid monoamine metabolites from cerebrospinal fluid. Brain Res (1969) 0.83
Neuroloeptic effect on desipramine steady-state plasma concentratins. Am J Psychiatry (1980) 0.83
Plasma catecholamine metabolites in subtypes of major depression. Biol Psychiatry (1987) 0.83
Homovanillic acid (HVA) and 5-hydroxyindoleacetic acid (5HIAA) during L-dopa therapy of Parkinson's disease. Neurology (1970) 0.83
Decreased digital flow persists after the abatement of cocaine-induced hemodynamic stimulation. Anesth Analg (1997) 0.83
Choline in cerebrospinal fluid. Life Sci (1967) 0.83
COMT Val158Met modulates subjective responses to intravenous nicotine and cognitive performance in abstinent smokers. Pharmacogenomics J (2013) 0.82
Cerebrospinal fluid 5-hydroxyindoles and behavior after L-tryptophan and pyridoxine adminstration to psychiatric patients. Neuropharmacology (1970) 0.82
CSF amine metabolites, clinical symptoms, and body movement in psychiatric patients. Biol Psychiatry (1976) 0.82
Plasma free homovanillic acid (HVA) as a predictor of clinical response in acute psychosis. Biol Psychiatry (1991) 0.82
Characteristics of desipramine-refractory depression. J Clin Psychiatry (1994) 0.81
Vulnerability to psychosis associated with hallucinogen use. Psychiatry Res (1983) 0.81
Methaqualone overdose: analytical methodology, and the significance of serum drug concentrations. Clin Chem (1973) 0.81
Plasma catecholamine metabolites and early response to haloperidol. J Clin Psychiatry (1984) 0.81
Measurement of benzoylecgonine and cocaine in urine, separation of various cocaine metabolites using reversed-phase high-performance liquid chromatography. J Chromatogr (1978) 0.81
Desipramine treatment of major depression in patients over 75 years of age. J Clin Psychopharmacol (1995) 0.81
CSF monoamine metabolites in child and adult psychiatric patients. A developmental perspective. Arch Gen Psychiatry (1980) 0.81
Amoxapine overdose: a case report. Am J Psychiatry (1982) 0.81
Lithium treatment in a very elderly nursing home population. Compr Psychiatry (1983) 0.81
Reduced cerebrospinal fluid 5-hydroxyindoleacetic acid and homovanillic acid in children with epilepsy. Neurology (1975) 0.81
Factors influencing maintenance and release of acetylcholine in rat cortical brain slices. Int J Neuropharmacol (1967) 0.81
Cerebrospinal fluid 5-hydroxyindoleactiic acid and homovanillic acid in psychiatric patients. Int J Neuropharmacol (1969) 0.80
5-Hydroxyindoleacetic acid in rat forebrain and cerebrospinal fluid following dorsal and median midbrain raphe lesions. Brain Res (1972) 0.80
Testosterone-patch-induced psychotic mania. Am J Psychiatry (1999) 0.80
Monozygotic twins concordant for response to clozapine. Lancet (1996) 0.80
Rapid desipramine dose adjustment using 24-hour levels. J Clin Psychopharmacol (1987) 0.80
The expanding indications for clozapine. Exp Clin Psychopharmacol (1997) 0.80
Grieving and unplanned pregnancy. Psychiatry (1976) 0.80
Pyrimethamine analysis by enzyme inhibition and HPLC assays. Am J Clin Pathol (1995) 0.80